Abstract Library

#4668 Predictive factors of postoperative recurrence in patients with neuroendocrine tumour of the lung: Prospective analysis of clinicopathologic features and radiomics

Introduction: In localised and locally advanced forms neuroendocrine tumours (NETs) of the lung radical surgical resection represents the standard of care, several clinicopathologic factors are potentially associated with recurrence of disease.

Conference:

Presenting Author: Paravani P

Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,

Keywords: radiomics, predictive role, rfs, lung, lung net,

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4656 Development of a 3D patient-derived extracellular matrix hydrogel model of small intestinal neuroendocrine tumour and mesenteric fibrosis

Introduction: The pathogenesis of mesenteric fibrosis in small intestinal neuroendocrine tumours (SI-NETs) is poorly understood, limiting development of effective treatments and biomarkers. A major barrier to research is the lack of disease models.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Webster A,

Keywords: small intestine, neuroendocrine, 3D model, hydrogel, fibrosis,